Similarly, MDS patients with a LEP promoter methylation above the cutoff had a significantly higher risk of progression (p = 0.007) (Fig. 5) and a shorter progression-free survival (PFS) (median PFS; 12 vs. 23.5 months, p = 0.003) (Fig. 4B). The gene discussed is LEP; the disease is myelodysplastic syndrome.